SG10201808870TA - Treatment of b-cell malignancies by a combination jak and pi3k inhibitor - Google Patents
Treatment of b-cell malignancies by a combination jak and pi3k inhibitorInfo
- Publication number
- SG10201808870TA SG10201808870TA SG10201808870TA SG10201808870TA SG10201808870TA SG 10201808870T A SG10201808870T A SG 10201808870TA SG 10201808870T A SG10201808870T A SG 10201808870TA SG 10201808870T A SG10201808870T A SG 10201808870TA SG 10201808870T A SG10201808870T A SG 10201808870TA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- cell malignancies
- pi3k inhibitor
- combination
- jak
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3K .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461976815P | 2014-04-08 | 2014-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201808870TA true SG10201808870TA (en) | 2018-11-29 |
Family
ID=52988487
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808870TA SG10201808870TA (en) | 2014-04-08 | 2015-04-07 | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| SG10201912229XA SG10201912229XA (en) | 2014-04-08 | 2015-04-07 | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| SG11201608434TA SG11201608434TA (en) | 2014-04-08 | 2015-04-07 | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912229XA SG10201912229XA (en) | 2014-04-08 | 2015-04-07 | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| SG11201608434TA SG11201608434TA (en) | 2014-04-08 | 2015-04-07 | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10064866B2 (en) |
| EP (2) | EP3795152A1 (en) |
| JP (4) | JP6537527B2 (en) |
| KR (3) | KR20220066179A (en) |
| CN (2) | CN106413716B (en) |
| AU (3) | AU2015244044B2 (en) |
| CA (2) | CA3158254A1 (en) |
| CL (1) | CL2016002566A1 (en) |
| CY (1) | CY1123603T1 (en) |
| DK (1) | DK3129021T3 (en) |
| EA (2) | EA201692011A1 (en) |
| ES (1) | ES2829914T3 (en) |
| HR (1) | HRP20201887T1 (en) |
| HU (1) | HUE051625T2 (en) |
| IL (4) | IL295225A (en) |
| LT (1) | LT3129021T (en) |
| MA (2) | MA54622A (en) |
| MX (2) | MX2020004398A (en) |
| MY (1) | MY185686A (en) |
| NZ (2) | NZ763326A (en) |
| PH (1) | PH12016501987A1 (en) |
| PL (1) | PL3129021T3 (en) |
| PT (1) | PT3129021T (en) |
| RS (1) | RS61058B1 (en) |
| SG (3) | SG10201808870TA (en) |
| SI (1) | SI3129021T1 (en) |
| UA (1) | UA119767C2 (en) |
| WO (1) | WO2015157257A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| RS58449B1 (en) | 2007-06-13 | 2019-04-30 | Incyte Holdings Corp | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| EP3643312A1 (en) | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| CN102985417B (en) | 2010-03-10 | 2015-01-28 | 因塞特公司 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| EA035981B1 (en) | 2010-05-21 | 2020-09-09 | Инсайт Холдингс Корпорейшн | Jak inhibitor formulation for topical application |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| PL3409278T3 (en) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
| MX2015005428A (en) * | 2012-11-01 | 2015-07-21 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors. |
| CN113384545A (en) | 2012-11-15 | 2021-09-14 | 因赛特公司 | Sustained release dosage forms of ruxolitinib |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| US9200004B2 (en) | 2013-01-15 | 2015-12-01 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| SI3489239T1 (en) | 2013-03-06 | 2022-04-29 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| EA201690357A1 (en) | 2013-08-07 | 2016-07-29 | Инсайт Корпорейшн | DOSAGE FORMS WITH Slow Release For JAK1 Inhibitor |
| SG11201601259YA (en) | 2013-08-23 | 2016-03-30 | Incyte Corp | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| MX2020004398A (en) | 2014-04-08 | 2022-06-06 | Incyte Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor. |
| MX2016014192A (en) | 2014-04-30 | 2017-05-01 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto. |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (en) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Salts of a pim kinase inhibitor |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3371190B1 (en) | 2015-11-06 | 2022-03-30 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| DK3360878T3 (en) | 2015-12-11 | 2020-11-09 | Sichuan Kelun Biotech Biopharmaceutica Co Ltd | Azetidine derivative, its manufacturing process and its use |
| AR107293A1 (en) | 2016-01-05 | 2018-04-18 | Incyte Corp | PIRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-g INHIBITORS |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| US10738057B2 (en) | 2017-10-18 | 2020-08-11 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SI3746429T1 (en) | 2018-01-30 | 2023-01-31 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
| CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| CN108484468A (en) * | 2018-05-11 | 2018-09-04 | 南京大学 | The preparation method of aryl azetidin compounds |
| WO2020051169A1 (en) | 2018-09-05 | 2020-03-12 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor |
| CN111320633B (en) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | Pyrrole/imidazo six-membered heteroaromatic ring compound and preparation method and medical application thereof |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20230190755A1 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of PI3K-delta inhibitors |
| KR102582097B1 (en) | 2022-12-28 | 2023-09-25 | (주)메디언스 | Janus kinase inhibitors and use thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| DE69942097D1 (en) | 1998-08-11 | 2010-04-15 | Novartis Ag | ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-HEMMENDER EFFECT |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| PT1294358E (en) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | MOORING PROCESS BY HUMIDITY |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| JP4959918B2 (en) | 2001-10-30 | 2012-06-27 | ノバルティス アーゲー | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| AR037647A1 (en) | 2002-05-29 | 2004-12-01 | Novartis Ag | USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (en) | 2003-09-24 | 2005-12-19 | Novartis Ag | DERIVATIVES OF ISOQUINOLINE AS INHIBITORS OF B-RAF |
| EP1885352A2 (en) | 2004-11-24 | 2008-02-13 | Novartis AG | Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| WO2008001115A2 (en) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
| CL2008001709A1 (en) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others. |
| RS58449B1 (en) | 2007-06-13 | 2019-04-30 | Incyte Holdings Corp | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| RU2011116928A (en) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | HETEROCYCLIC INHIBITORS JAK KINASES |
| CL2009001884A1 (en) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye. |
| JOP20190231A1 (en) | 2009-01-15 | 2017-06-16 | Incyte Corp | Processes for preparing jak inhibitors and related intermediate compounds |
| CA2702567A1 (en) | 2009-04-28 | 2010-10-28 | Katch Kan Holdings Ltd. | Apparatus and method for stripping solids and fluids from a string used in drilling or servicing wells |
| EP3643312A1 (en) | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| AU2010249380B2 (en) * | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
| PL2448938T3 (en) * | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pyrimidinones as pi3k inhibitors |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| KR20120046723A (en) * | 2009-07-02 | 2012-05-10 | 노파르티스 아게 | 2-carboxamide cycloamino ureas useful as pi3k inhibitors |
| DK2470546T3 (en) | 2009-08-28 | 2013-10-14 | Takeda Pharmaceutical | HEXAHYDROOXAZINOPTERIDIN compounds for use as mTOR INHIBITORS |
| AR078012A1 (en) | 2009-09-01 | 2011-10-05 | Incyte Corp | HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| BR112012020693B1 (en) | 2010-02-18 | 2020-05-12 | Incyte Holdings Corporation | CYCLLOBUTAN AND METHYLCYCLOBUTAN DERIVATIVES AS JANUS KINASE INHIBITORS AND COMPOSITION THAT UNDERSTANDS |
| CN102985417B (en) | 2010-03-10 | 2015-01-28 | 因塞特公司 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| EA035981B1 (en) | 2010-05-21 | 2020-09-09 | Инсайт Холдингс Корпорейшн | Jak inhibitor formulation for topical application |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| US9358229B2 (en) * | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
| KR101982475B1 (en) | 2011-09-02 | 2019-05-27 | 인사이트 홀딩스 코포레이션 | Heterocyclylamines as pi3k inhibitors |
| UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
| EP2780017A1 (en) | 2011-11-15 | 2014-09-24 | Novartis AG | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
| AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
| TW201406761A (en) | 2012-05-18 | 2014-02-16 | Incyte Corp | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| MX2015005428A (en) | 2012-11-01 | 2015-07-21 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors. |
| CN113384545A (en) | 2012-11-15 | 2021-09-14 | 因赛特公司 | Sustained release dosage forms of ruxolitinib |
| TWI657090B (en) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
| SI3489239T1 (en) | 2013-03-06 | 2022-04-29 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| ES2845210T3 (en) | 2013-05-17 | 2021-07-26 | Incyte Corp | Bipirazole derivatives as JAK inhibitors |
| EA201690357A1 (en) | 2013-08-07 | 2016-07-29 | Инсайт Корпорейшн | DOSAGE FORMS WITH Slow Release For JAK1 Inhibitor |
| EP3035966A1 (en) | 2013-08-20 | 2016-06-29 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| WO2015131031A1 (en) | 2014-02-28 | 2015-09-03 | Incyte Corporation | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| MX2020004398A (en) | 2014-04-08 | 2022-06-06 | Incyte Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor. |
| MX2016014192A (en) | 2014-04-30 | 2017-05-01 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto. |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| ES2843522T3 (en) | 2015-02-27 | 2021-07-19 | Incyte Corp | PI3K inhibitor salts and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183062A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one |
-
2015
- 2015-04-07 MX MX2020004398A patent/MX2020004398A/en unknown
- 2015-04-07 KR KR1020227015341A patent/KR20220066179A/en not_active Application Discontinuation
- 2015-04-07 EP EP20191540.2A patent/EP3795152A1/en active Pending
- 2015-04-07 JP JP2016561810A patent/JP6537527B2/en active Active
- 2015-04-07 CN CN201580018986.8A patent/CN106413716B/en active Active
- 2015-04-07 MA MA054622A patent/MA54622A/en unknown
- 2015-04-07 PL PL15717381T patent/PL3129021T3/en unknown
- 2015-04-07 NZ NZ763326A patent/NZ763326A/en unknown
- 2015-04-07 SI SI201531432T patent/SI3129021T1/en unknown
- 2015-04-07 CA CA3158254A patent/CA3158254A1/en active Pending
- 2015-04-07 RS RS20201374A patent/RS61058B1/en unknown
- 2015-04-07 MA MA39984A patent/MA39984B1/en unknown
- 2015-04-07 SG SG10201808870TA patent/SG10201808870TA/en unknown
- 2015-04-07 KR KR1020237009340A patent/KR20230044320A/en not_active Application Discontinuation
- 2015-04-07 LT LTEP15717381.6T patent/LT3129021T/en unknown
- 2015-04-07 MX MX2016013182A patent/MX2016013182A/en active IP Right Grant
- 2015-04-07 NZ NZ725778A patent/NZ725778A/en unknown
- 2015-04-07 EA EA201692011A patent/EA201692011A1/en unknown
- 2015-04-07 WO PCT/US2015/024676 patent/WO2015157257A1/en active Application Filing
- 2015-04-07 AU AU2015244044A patent/AU2015244044B2/en active Active
- 2015-04-07 PT PT157173816T patent/PT3129021T/en unknown
- 2015-04-07 MY MYPI2016001813A patent/MY185686A/en unknown
- 2015-04-07 EP EP15717381.6A patent/EP3129021B1/en active Active
- 2015-04-07 ES ES15717381T patent/ES2829914T3/en active Active
- 2015-04-07 HU HUE15717381A patent/HUE051625T2/en unknown
- 2015-04-07 DK DK15717381.6T patent/DK3129021T3/en active
- 2015-04-07 SG SG10201912229XA patent/SG10201912229XA/en unknown
- 2015-04-07 UA UAA201611143A patent/UA119767C2/en unknown
- 2015-04-07 KR KR1020167030793A patent/KR102396717B1/en active IP Right Grant
- 2015-04-07 EA EA202191009A patent/EA202191009A1/en unknown
- 2015-04-07 SG SG11201608434TA patent/SG11201608434TA/en unknown
- 2015-04-07 CN CN202010157115.7A patent/CN111494386A/en active Pending
- 2015-04-07 US US14/680,659 patent/US10064866B2/en active Active
- 2015-04-07 IL IL295225A patent/IL295225A/en unknown
- 2015-04-07 CA CA2945151A patent/CA2945151C/en active Active
-
2016
- 2016-10-06 IL IL248198A patent/IL248198B/en active IP Right Grant
- 2016-10-06 PH PH12016501987A patent/PH12016501987A1/en unknown
- 2016-10-07 CL CL2016002566A patent/CL2016002566A1/en unknown
-
2018
- 2018-07-27 US US16/047,853 patent/US10675284B2/en active Active
-
2019
- 2019-06-04 JP JP2019104593A patent/JP6862495B2/en active Active
-
2020
- 2020-04-05 IL IL273802A patent/IL273802B/en unknown
- 2020-05-12 US US16/872,794 patent/US20210093638A1/en not_active Abandoned
- 2020-08-05 AU AU2020213313A patent/AU2020213313B2/en active Active
- 2020-11-26 HR HRP20201887TT patent/HRP20201887T1/en unknown
- 2020-12-07 CY CY20201101154T patent/CY1123603T1/en unknown
-
2021
- 2021-03-31 JP JP2021059028A patent/JP7206314B2/en active Active
- 2021-11-18 IL IL288231A patent/IL288231B2/en unknown
-
2022
- 2022-07-18 AU AU2022206693A patent/AU2022206693A1/en active Pending
-
2023
- 2023-01-04 JP JP2023000189A patent/JP2023040142A/en active Pending
- 2023-05-08 US US18/144,593 patent/US20240091234A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501987A1 (en) | Treatment of b-cell malignancies by a combination jak and p13k inhibitor | |
| HK1247922A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| MX2020003702A (en) | Cyclopropylamines as lsd1 inhibitors. | |
| PH12016502099A1 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors | |
| MX2018016193A (en) | Methods of treating ovarian cancer. | |
| PH12016502177A1 (en) | Processes of preparing a jak1 inhibitor and new forms thereto | |
| MX2018006632A (en) | Bicyclic inhibitors of pad4. | |
| EA201792227A1 (en) | TREATMENT OF LUNG CANCER WITH GLUTAMINASE INHIBITORS | |
| MX2016013600A (en) | Method of treating lung adenocarcinoma. | |
| MX2019013808A (en) | Compounds for treatment of cancer. | |
| MA40457A (en) | Drug combinations to treat multiple myeloma | |
| MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
| IL261667B (en) | Use of braf inhibitors for treating cutaneous reactions | |
| EA201692332A1 (en) | Bordeaux Proteas Inhibitors for Use After Primary Anti-Cancer Therapy | |
| MX2017009632A (en) | Combination therapy using a cd19-adc and vincristine. | |
| MY178971A (en) | Triaminopyrimidine compounds useful for preventing or treating malaria | |
| MY197096A (en) | Treatment of b-cell malignancies by a combination jak and p13k inhibitor |